Elliot and Roslyn Jaffe Food Allergy Institute

Search results

• A Food-Allergy Fix Hiding in Plain Sight

  Sicherer, S.

  9/09/24

  1 item of Media coverage

  Press/Media

• A Better Fix for Food Allergies

  Sicherer, S.

  9/09/24

  3 items of Media coverage

  Press/Media

• Reports from Icahn School of Medicine at Mount Sinai Advance Knowledge in Eosinophilic Esophagitis (Dupilumab for Eosinophilic Esophagitis In Patients 1 To 11 Years of Age)

  Chehade, M.

  21/08/24

  1 item of Media coverage

  Press/Media

• Where Does Nasal Spray Epinephrine Fit in Allergy Treatment?

  Sicherer, S.

  20/08/24

  1 item of Media coverage

  Press/Media

• Gastroenterology Month in Review: July 2024; The July 2024 gastroenterology month in review highlights FDA news, GI pipeline updates, and a new clinical practice update from the American Gastroenterological Assocation.

  Chehade, M.

  3/08/24

  2 items of Media coverage

  Press/Media

• Gastroenterology Month in Review: July 2024

  Chehade, M.

  3/08/24

  2 items of Media coverage

  Press/Media

• Top news of July: Anaphylaxis guidelines, epinephrine, FDA applications, more

  Chehade, M. & Guttman, E.

  1/08/24

  1 item of Media coverage

  Press/Media

• Egg Oral Immunotherapy Leads to More Rapid Egg Allergy Desensitization than Baked-egg Products

  Sampson, H.

  17/07/24

  1 item of Media coverage

  Press/Media

• Regeneron: Dupixent Positive Phase 3 Data in Children with Eosinophilic Esophagitis Published in NEJM

  Chehade, M.

  12/07/24

  1 item of Media coverage

  Press/Media

• Phase 3 Trial Highlights Efficacy of Dupilumab for EoE in Children Aged 1 to 11

  Chehade, M.

  11/07/24

  1 item of Media coverage

  Press/Media

• Dupixent Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

  Chehade, M.

  11/07/24

  1 item of Media coverage

  Press/Media

• United Kingdom : Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

  Chehade, M.

  9/07/24

  2 items of Media coverage

  Press/Media

• Regeneron: Dupixent Positive Phase 3 Data in Children with Eosinophilic Esophagitis Published in NEJM

  Chehade, M.

  9/07/24

  1 item of Media coverage

  Press/Media

• Mirna Chehade, MD, MPH: “Exciting” Phase 3 Data for Dupilumab in Pediatric Eosinophilic Esophagitis

  Chehade, M.

  8/07/24

  2 items of Media coverage

  Press/Media

• Mirna Chehade, MD, MPH: "Exciting" Phase 3 Data for Dupilumab in Pediatric Eosinophilic Esophagitis; Chehade reviews key findings from the phase 3 EoE kids trial and how they inform dupilumab's use in children 1-11 years of age with eosinophilic esophagit

  Chehade, M.

  8/07/24

  2 items of Media coverage

  Press/Media

• Dupilumab Helps Pediatric Patients With Eosinophilic Esophagitis Achieve Histologic Remission

  Chehade, M.

  5/07/24

  1 item of Media coverage

  Press/Media

• Regeneron: Dupixent Positive Phase 3 Data in Children with Eosinophilic Esophagitis Published in NEJM

  Chehade, M.

  3/07/24

  1 item of Media coverage

  Press/Media

• Children achieve remission in eosinophilic esophagitis with dupilumab

  Chehade, M.

  3/07/24

  1 item of Media coverage

  Press/Media

• Regeneron: Dupixent Positive Phase 3 Data in Children with Eosinophilic Esophagitis Published in NEJM

  Chehade, M.

  2/07/24

  1 item of Media coverage

  Press/Media

• US SECTOR WEEKLY: PRESS RELEASES OF LISTED COMPANIES IN THE MEDICAL SECTOR FRIDAY JUNE 28, 2024

  Chehade, M.

  28/06/24

  1 item of Media coverage

  Press/Media

• Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

  Chehade, M.

  26/06/24 → 27/06/24

  3 items of Media coverage

  Press/Media

• US SECTOR DAILY: PRESS RELEASES OF LISTED COMPANIES IN THE MEDICAL SECTOR THURSDAY JUNE 27, 2024

  Chehade, M.

  27/06/24

  1 item of Media coverage

  Press/Media

• Sanofi: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

  Chehade, M.

  26/06/24 → 27/06/24

  3 items of Media coverage

  Press/Media

• Dupilumab Ups Histologic Response for Pediatric Eosinophilic Esophagitis

  Chehade, M.

  27/06/24

  1 item of Media coverage

  Press/Media

• Weight-tiered higher doses of dupilumab improves key disease measures of EoE

  Chehade, M.

  27/06/24

  1 item of Media coverage

  Press/Media